Trevena Stock Forecast, Price & News

Trevena (NASDAQ:TRVN) Frequently Asked Questions

Is Trevena a buy right now?

2 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Trevena in the last twelve months. There are currently 1 hold rating and 1 buy rating for the stock. The consensus among Wall Street analysts is that investors should "buy" Trevena stock.
View analyst ratings for Trevena or view top-rated stocks.

What stocks does MarketBeat like better than Trevena?

Wall Street analysts have given Trevena a "Buy" rating, but there may be better buying opportunities in the stock market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new stock ideas, but Trevena wasn't one of them. MarketBeat thinks these five companies may be even better buys.
View MarketBeat's top stock picks here.

When is Trevena's next earnings date?

Trevena is scheduled to release its next quarterly earnings announcement on Monday, November 1st 2021.
View our earnings forecast for Trevena.

How were Trevena's earnings last quarter?

Trevena, Inc. (NASDAQ:TRVN) issued its quarterly earnings data on Thursday, August, 12th. The biopharmaceutical company reported ($0.09) EPS for the quarter, missing analysts' consensus estimates of ($0.08) by $0.01. The biopharmaceutical company had revenue of $0.18 million for the quarter, compared to analyst estimates of $1.26 million. Trevena had a negative net margin of 1,194.62% and a negative trailing twelve-month return on equity of 40.89%.
View Trevena's earnings history.

How has Trevena's stock price been impacted by Coronavirus?

Trevena's stock was trading at $0.6984 on March 11th, 2020 when Coronavirus reached pandemic status according to the World Health Organization (WHO). Since then, TRVN shares have increased by 63.2% and is now trading at $1.14.
View which stocks have been most impacted by COVID-19.

What price target have analysts set for TRVN?

2 analysts have issued 1-year price targets for Trevena's shares. Their forecasts range from $6.00 to $6.00. On average, they anticipate Trevena's share price to reach $6.00 in the next year. This suggests a possible upside of 426.3% from the stock's current price.
View analysts' price targets for Trevena or view top-rated stocks among Wall Street analysts.

Who are Trevena's key executives?

Trevena's management team includes the following people:

• Carrie L. Bourdow, President, Chief Executive Officer & Director
• Barry Shin, Chief Financial Officer & Senior Vice President
• Mark A. Demitrack, Chief Medical Officer & Senior Vice President
• Angela Bagley, Vice President-Technical Operations
• Michael J. Fossler, VP-Clinical Development & Quantitative Sciences

Who are some of Trevena's key competitors?

Some companies that are related to Trevena include Oramed Pharmaceuticals (ORMP), Kiniksa Pharmaceuticals (KNSA), Dyne Therapeutics (DYN), POINT Biopharma Global (PNT), OrganiGram (OGI), Gracell Biotechnologies (GRCL), Eagle Pharmaceuticals (EGRX), Silence Therapeutics (SLN), Emisphere Technologies (EMIS), Amryt Pharma (AMYT), Annexon (ANNX), Cara Therapeutics (CARA), Veru (VERU), Immuneering (IMRX) and DiaMedica Therapeutics (DMCAF).
View all of TRVN's competitors.

What other stocks do shareholders of Trevena own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Trevena investors own include Conatus Pharmaceuticals (CNAT), Novavax (NVAX), Sorrento Therapeutics (SRNE), ADMA Biologics (ADMA), SCYNEXIS (SCYX), Matinas BioPharma (MTNB), Zosano Pharma (ZSAN), Aeterna Zentaris (AEZS), Bionano Genomics (BNGO) and Dynavax Technologies (DVAX).

What is Trevena's stock symbol?

Trevena trades on the NASDAQ under the ticker symbol "TRVN."

Who are Trevena's major shareholders?

Trevena's stock is owned by many different retail and institutional investors. Top institutional investors include NEXT Financial Group Inc (0.03%) and IFP Advisors Inc (0.01%).
View institutional ownership trends for Trevena.

Which institutional investors are selling Trevena stock?

TRVN stock was sold by a variety of institutional investors in the last quarter, including IFP Advisors Inc.
View insider buying and selling activity for Trevena or view top insider-selling stocks.

Which institutional investors are buying Trevena stock?

TRVN stock was purchased by a variety of institutional investors in the last quarter, including NEXT Financial Group Inc.
View insider buying and selling activity for Trevena or or view top insider-buying stocks.

How do I buy shares of Trevena?

Shares of TRVN can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Trevena's stock price today?

One share of TRVN stock can currently be purchased for approximately $1.14.

How much money does Trevena make?

Trevena has a market capitalization of $187.54 million and generates $3.07 million in revenue each year. The biopharmaceutical company earns $-29.37 million in net income (profit) each year or ($0.23) on an earnings per share basis.

How many employees does Trevena have?

Trevena employs 25 workers across the globe.

What is Trevena's official website?

The official website for Trevena is www.trevena.com.

Where are Trevena's headquarters?

Trevena is headquartered at 955 Chesterbrook Boulevard Suite 110, Chesterbrook PA, 19087.

How can I contact Trevena?

Trevena's mailing address is 955 Chesterbrook Boulevard Suite 110, Chesterbrook PA, 19087. The biopharmaceutical company can be reached via phone at (610) 354-8840 or via email at [email protected].